Free Trial
NASDAQ:RVPH

Reviva Pharmaceuticals (RVPH) Stock Price, News & Analysis

Reviva Pharmaceuticals logo
$0.98
-0.14 (-12.53%)
(As of 11/1/2024 ET)

About Reviva Pharmaceuticals Stock (NASDAQ:RVPH)

Key Stats

Today's Range
$0.96
$1.15
50-Day Range
$0.98
$1.50
52-Week Range
$0.60
$6.30
Volume
796,682 shs
Average Volume
287,988 shs
Market Capitalization
$32.69 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.50
Consensus Rating
Buy

Company Overview

Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis. It is also developing RP1208 for the treatment of depression and obesity. Reviva Pharmaceuticals Holdings, Inc. was founded in 2018 and is headquartered in Cupertino, California.

Reviva Pharmaceuticals Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
41st Percentile Overall Score

RVPH MarketRank™: 

Reviva Pharmaceuticals scored higher than 41% of companies evaluated by MarketBeat, and ranked 719th out of 975 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Reviva Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Reviva Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.

  • Read more about Reviva Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Reviva Pharmaceuticals are expected to grow in the coming year, from ($0.98) to ($0.81) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Reviva Pharmaceuticals is -0.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Reviva Pharmaceuticals is -0.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Reviva Pharmaceuticals has a P/B Ratio of 4.89. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Reviva Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    15.88% of the outstanding shares of Reviva Pharmaceuticals have been sold short.
  • Short Interest Ratio / Days to Cover

    Reviva Pharmaceuticals has a short interest ratio ("days to cover") of 11.1, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Reviva Pharmaceuticals has recently decreased by 2.93%, indicating that investor sentiment is improving.
  • Dividend Yield

    Reviva Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Reviva Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    15.88% of the outstanding shares of Reviva Pharmaceuticals have been sold short.
  • Short Interest Ratio / Days to Cover

    Reviva Pharmaceuticals has a short interest ratio ("days to cover") of 11.1, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Reviva Pharmaceuticals has recently decreased by 2.93%, indicating that investor sentiment is improving.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Reviva Pharmaceuticals this week, compared to 1 article on an average week.
  • Search Interest

    Only 2 people have searched for RVPH on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added Reviva Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Reviva Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    31.83% of the stock of Reviva Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    63.18% of the stock of Reviva Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Reviva Pharmaceuticals' insider trading history.
Receive RVPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Reviva Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

RVPH Stock News Headlines

Reviva to Participate in the UBS Global Healthcare Conference
625,000% Gain
Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.
Reviva Pharmaceuticals Holdings, Inc. (RVPHW)
See More Headlines

RVPH Stock Analysis - Frequently Asked Questions

Reviva Pharmaceuticals' stock was trading at $5.15 on January 1st, 2024. Since then, RVPH shares have decreased by 81.0% and is now trading at $0.9775.
View the best growth stocks for 2024 here
.

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) posted its quarterly earnings results on Wednesday, August, 14th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.28) by $0.02.

Shares of RVPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Reviva Pharmaceuticals investors own include Sangamo Therapeutics (SGMO), Salesforce (CRM), Adobe (ADBE), Advanced Micro Devices (AMD), CrowdStrike (CRWD), Airbnb (ABNB) and Marvell Technology (MRVL).

Company Calendar

Last Earnings
8/14/2024
Today
11/02/2024
Next Earnings (Estimated)
11/12/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:RVPH
Fax
N/A
Employees
5
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$15.50
High Stock Price Target
$17.00
Low Stock Price Target
$14.00
Potential Upside/Downside
+1,485.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-39,260,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.20 per share

Miscellaneous

Free Float
22,797,000
Market Cap
$32.69 million
Optionable
Optionable
Beta
-0.09
10 Best Stocks to Own in 2025 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio.

Get This Free Report

This page (NASDAQ:RVPH) was last updated on 11/2/2024 by MarketBeat.com Staff
From Our Partners